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1. Introduction 
1.1. Insulin: physicochemical properties and function 
Insulin is a hormone that is synthesized in the β-cells of the pancreas as a proinsulin 
precursor and is converted to insulin by enzymatic cleavage. The resulting insulin molecule 
is composed of 51 amino acids arranged into two polypeptide chains - the A and B chains - 
which are connected by two interchain disulphide bridges. In the A chain, there is an 
additional intrachain disulphide linkage [1]. The primary structure of human insulin is 
shown in Figure 1 a. In the secondary structure, chain A consists of two antiparallel α-
helices (A2 to A8 and A13 to A20), while chain B forms a single α-helix “B9 to B19” followed by 
a turn and a β strand “B21 and B30” [2]. The folding of insulin into a tertiary structure is 
essential for its biological activity (Figure 1b). Insulin has an isoelectric point (pI) of 5.3 and a 
charge of -2 to -6 in the pH range 7-11. Another intrinsic property of insulin is its ability to 
readily associate into dimmers, hexamers and higher-order aggregates. At the low 
concentrations found in the blood stream (< 10-3 µM), insulin exists as a monomer, which is 
its biologically active form. Following biosynthesis, insulin is stored as crystalline zinc-
bound hexamers in vesicles within the pancreatic β-cells from which secretion occurs in 
response to elevated blood glucose levels [3]. The biological actions of insulin are initiated 
when insulin binds to its cell surface receptor. Insulin is an anabolic hormone and when 
binding to its receptor begins, many protein activation cascades occur. These include: the 
translocation of the glucose transporter to the plasma membrane and the influx of glucose, 
glycogen synthesis, glycolysis and fatty acid synthesis. Insulin has been observed as 
promoting the transport of some amino acids and potassium ions. Insulin also inhibits the 
liberation of free fatty acids and glycerol from the adipose tissue [3]. 
Insulin is used for the treatment of diabetes, a disease which results from a defect in the 
secretion or action of insulin.  
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Figure 1. Insulin: a) Primary Structure b) Tertiary Structure 
1.2. Oral delivery of insulin: Why? 
Insulin is introduced by the parenteral route and two or three injections are needed for the 
better control of diabetes and in order to reduce the long term complications of 
hyperglycaemia (retinopathy, neuropathy and nephropathy). Patient non-compliance is 
common with the parenteral route. In addition, repeated injections will cause lipoatrophy or 
lipohypertrophy. Moreover, insulin injected into the subcutaneous tissues goes directly into 
general circulation and leads to peripheral hyperinsulinemia, which is associated with 
peripheral hypertension, the development of atherosclerosis, cancer, hypoglycaemia and 
other adverse metabolic effects [4]. Thus, the conventional subcutaneous injection of insulin 
is unphysiological because it deprives patients of the benefits of portal insulin since the liver 
is the major metabolic modulator of the glucose metabolism. 
Oral insulin is a dream of patients and a challenge for scientists. For patients, not only are 
the pain and stress of injections relieved but it may also protect beta cells, avoid the weight 
gain associated with insulin injections and correct the blunting of the first-phase release of 
insulin [5]. All these effects are due to the fact that oral route provide insulin directly to the 
liver through portal circulation, resembling that which occurs in the non-diabetic individual 
[6]. The achievement of an adequate level of insulin in portal circulation has been associated 
with more a rapid and significant lowering of plasma glucose and haemoglobin A1c levels, 
the normalization of the plasma levels of three carbon precursors - such as lactate, pyruvate 
and alanine - and the hormones cortisol, growth hormone and glucagon [7]. 
Another advantage of oral insulin is that the gastrointestinal tract is immune tolerant 
compared to other routes of drug administration since immunogenicity has become a major 
issue for most biotechnology products. Immunogenicity decreases in the following order: 
(inhalation > subcutaneous > intramuscular > intravenous > oral). 
For scientists, greater effort is needed to develop a nontoxic, stable, bioactive oral insulin 
delivery system. To develop such systems, many barriers must be explored.  
1.3. Obstacles to oral delivery 
The major barrier is that of absorption through the gastrointestinal membrane. Generally, 
the absorption of molecules can occur through the paracellular or the transcellular route. 
A B 
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The former is the preferred route for small hydrophilic molecules with a molecular weight 
below 500 Da [8]. Of course, molecules with a high molecular weight - such as insulin (about 
6 KDa) - would not penetrate through this route. This large molecular size, its charge and its 
hydrophilicity all preclude insulin absorption by transcellular diffusion.  
Another obstacle is those enzymes that are located throughout the GIT. In the stomach there 
is a family of aspartic proteases called pepsins. In the small intestine, pancreatic proteases 
consisting of the serine endopeptidase (trypsin, α-chymotrypsin, elastase and 
exopeptidases, carboxypeptidases A and B) are responsible for the degradation of proteins 
[9]. Other enzymes are located at the brush–border membrane (various peptidases) or 
within the enterocytes of the intestinal tract. It was demonstrated by Aoki et al. [10] that the 
enzymatic degradation activity for insulin in the mucous/glycocalyx layers tends to increase 
towards the upper small intestine in the following order: duodenum > jejunum > ileum. 
Another challenge for the formulator is the stability of insulin. Insulin has a delicate structure, 
and both formulation and processing parameters could influence its stability [11]. The most 
common degradation reactions are deamidation and polymerization. Extensive deamidation 
at the residue AsnA21 of insulin occurs in acid solutions, while in neutral formulations 
deamidation takes place at AsnB3 at a substantially reduced rate [12]. High temperatures 
accelerate the formation of covalent insulin dimer and covalent insulin polymer [13].   
The formulator could handle the enzyme and stability barriers. A well-formulated 
nanocarrier would protect insulin from enzymes. Also, and with the proper choice of 
excipients and a properly designed method of production, the stability of insulin could be 
preserved. Many investigated systems have overcome these two barriers. However, no 
system exhibits a reproducible and pronounced absorption.  
1.4. Approaches explored to overcome the obstacles  
To improve the bioavailability of insulin, different approaches have been explored, 
including chemical modification [14], co-administration with absorption enhancers and/or 
enzyme inhibitors [15] and incorporation into carriers, such as liposomes ]16], mixed 
micelles, lipid-based systems, microspheres and nanoparticles [17-20]. 
1.4.1. Nanocarriers 
These are carriers with a particle size of less than 1000 nm. Nanocarriers have received more 
attention recently due to their submicron size and their large specific surface area, both of 
which favour their absorption compared to larger carriers. 
1.4.1.1. Types 
Nanocarriers are categorized into: polymeric nanoparticles, nanovesicles and solid lipid 
nanoparticles (Figure 2). There are two types of polymeric nanoparticles: the matrix 
particles termed ‘nanospheres’ and the reservoir-type named ‘nanocapsules’. Vesicles have a 
hydrophilic core and hydrophobic bilayers. Conventionally, liposomal vesicles were 
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developed by the self-assembly of phospholipid molecules in an aqueous environment. 
Recently, polymeric vesicles were prepared from amphiphilic polymers which form 
aggregates in aqueous solutions [21]. Solid lipid nanoparticles (SLN) are submicron colloidal 
carriers prepared from solid lipids (lipids being solid at room and body temperatures), such 
as triacylglycerols, complex acylglycerol mixtures or waxes, and dispersed either in water or 
in an aqueous surfactant solution [22]. The important features of different nanocarriers are 
illustrated in Table 1. 
1.4.1.2. Applications 
1.4.1.2.1 Liposomes 
Insulin-loaded liposomes containing different kinds of bile salts (glycocholate, sodium 
taurocholate or sodium deoxycholate) were prepared by a reversed-phase evaporation 
method and their hypoglycaemic activity was assessed after oral administration to male 
Wistar rats. Liposomes containing sodium glycocholate elicited higher bioavailability - of 
approximately 8.5% and 11.0% - in non-diabetic and diabetic rats, respectively [23]. A 
hepatic-directed vesicle insulin system (HDV-I) was developed by Diasome Pharmaceuticals, 
Inc. The vesicles contain a specific proprietary hepatocyte-targeting molecule - biotin-
phosphatidylethanolamine - in their phospholipid bilayer. Clinical trials in adult patients 
with type 1 diabetes mellitus demonstrated that the postprandial glycaemic control produced 
by 0.1 and 0.2 U/kg oral HDV-I was similar to that produced by 0.07 U/kg SC Humulin R [7]. 
1.4.1.2.2. Polymeric nanovesicles 
Poly(lactic acid)-b-Pluronic-b-poly(lactic acid) block copolymers were synthesized [21]. This 
amphiphilic block copolymer aggregates in an aqueous solution to form vesicular 
nanoparticles. The oral administration of insulin-loaded vesicles to diabetic mice resulted in 
the reduction of blood glucose levels - 25% of the initial glucose level - which was 
maintained at this level for an additional 18.5 h [21].  
1.4.1.2.3. Solid Lipid Nanoparticles (SLN) 
Sarmento et al. [24] prepared insulin-loaded cetyl palmitate solid lipid nanoparticles and 
demonstrated their potential to deliver insulin orally. The drug loading capacity in solid 
lipid nanoparticles was improved by enhancing insulin liposolubility. Insulin was 
solubilized into mixed reverse micelles of sodium cholate and soybean phosphatidylcholine 
and transformed into SLN using a novel reverse micelle-double emulsion technique. Stearic 
acid and palmatic acid were used as a biocompatible lipid matrix [25]. The surface of the 
nanoparticles was modified by chitosan to enhance their penetration through GIT. In 
addition, chitosan was able to provide stealth properties to SLN, resulting in the absence of 
phagocytosis. Pharmacological availability values of 5.1–8.3% for SLN and 17.7% for 
chitosan-coated SLN were reported [26]. Lectins are proteins that bind sugar reversibly and 
are involved in many cell recognition and adhesion processes. They have been extensively 
adopted to target both absorptive enterocytes and M cells [27]. Wheat germ agglutinin binds 
(WGA) specifically to cell membranes and is taken up into cells by receptor-mediated 
endocytosis [28]. Zhang et al. [29] utilized the advantages of WGA and formulated SLN  
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Nanocarrier Advantages Shortcomings 
Polymeric 
nanocarriers 
Various polymeric materials 
(hydrophobic and hydrophilic) can be 
used to modulate the physicochemical 
properties of NPs (e.g., surface charge 
and mucoadhesivity), encapsulation 
efficiency, drug release profile and 
biological behaviour 
Denaturation can occur during 
encapsulation in synthetic 
polymers, due largely to 
exposure to organic solvents, 
elevated temperatures and 
aqueous organic interfaces. 
Cytotoxicity of polymers after 
internalization into cells 
Liposomes Good permeation property since their 
bilayer structure is similar to that of the 
cell membrane 
Poor entrapment efficiency 
Stability in biological fluids 
was relatively weak 
Polymeric 
nanovesicles 
More stable than liposomes 
The properties of polymeric vesicles, 
such as the size and the thickness of the 
bilayer, can be varied by changing the 
molecular weight and block composition 
of the polymer 
Cytotoxicity of polymers after 
internalization into cells 
Solid lipid 
nanoparticles 
Tolerability, Biodegradability 
Composed of physiological lipids, which 
minimizes the risk of acute and chronic 
toxicity. 
Possibility of production on a large 
industrial scale 
Poor encapsulation efficiency 
of water-soluble proteins and 
peptides into the lipid core 
The high temperatures 
required to melt the lipid may 
affect the stability of insulin 
Slow degradation 
Table 1. Nanocarriers: general advantages and shortcomings  
modified with WGA to enhance the oral delivery of insulin. Insulin-loaded SLNs or WGA-
modified SLNs were administered orally to rats and elicited relative pharmacological 
bioavailability values of 4.46% and 6.08% and relative bioavailability values of 4.99% and 
7.11%, respectively, in comparison with the subcutaneous injection of insulin.  
Polymeric nanoparticles developed from biocompatible and biodegradable polymers are 
good candidates for insulin delivery 
 
Figure 2. Types of nanocarriers 
Nanocapsules Nanospheres Liposomes Polymeric nanovesicles 
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1.4.1.3. Polymers used for the fabrication of polymeric nanoparticles 
Both synthetic and natural polymers were investigated for the production of nanosystems. 
These polymers may be used alone or in combination to develop nanoparticles. Several 
fabrication techniques have been developed and can generally be subdivided into two 
categories, according to whether a preformed polymer is used or else whether nanoparticles 
are formed during the polymerization reaction. Methods from the first category include: 
emulsification/solvent evaporation, solvent displacement and interfacial deposition, 
emulsification/solvent diffusion, salting out with synthetic polymers, ionotropic gelation, 
coacervation and polyelectrolyte complexation. Meanwhile, the methods of the second 
category are: emulsion polymerization, interfacial polymerization and interfacial 
polycondensation. These methods were thoroughly discussed by Reis et al. [30]. 
1.4.1.3.1. Synthetic polymers 
Usually, these are well-defined structures that can be modified to yield reasonable 
degradability and functionality. Synthetic biodegradable polymers such as poly ɛ-
caprolactone (PCL) poly (lactic-co-glycolic acid) (PLGA) and polylactides (PLA) are widely 
used in drug delivery due to their good biocompatibility, biodegradability and novel drug 
release behaviour. The chemical structures of synthetic polymers were depicted in Table 2 
and an example of insulin nanoparticles fabricated from these polymers is illustrated in 
Table 3. 
1.4.1.3.1.1. PLGA 
Poly (lactic-co-glycolic acid) (PLGA) is an aliphatic polyester synthetic biodegradable 
biopolymer which is successfully used for the development of nanomedicines. It was also 
investigated for the delivery of insulin. In the work of Yang et al. [31], insulin was 
encapsulated in PLGA nanoparticles. The administration of insulin-loaded PLGA 
nanoparticles for diabetes mellitus induced a rapid decrease in blood glucose levels for up 
to 24 h and increased insulin levels. The loading capacity was 78.35%. To facilitate loading 
efficiency, the lipophilicity of the insulin was increased by complexation with sodium lauryl 
sulphate or sodium oleate. Insulin encapsulation efficiency reached up to 90%. [32, 33]. 
Mucoadhesive PLGA nanoparticles were prepared to enhance the oral bioavailability of the 
negatively charged PLGA nanoparticles. The PLGA nanoparticles were coated with chitosan 
or Eudragit® RS (RS). The pharmacological availability of two kinds of nanoparticles - 
PLGA nanoparticles and chitosan-coated PLGA nanoparticles - relative to SC injection was 
calculated and found to be 7.6% and 10.5%, respectively, at an insulin dose of 15 IU/kg [34]. 
Meanwhile, the pharmacological availability of the 50 IU/kg Eudragit® RS (RS) coated 
PLGA nanoparticle was 9.2% [35]. The main shortcomings of PLGA are that the degradation 
products arising from degradation of PLGA (lactic and glycolic acid) result in the generation 
of acidic species which can provoke problems for long‐term stability when encapsulating 
bioactive molecules. Antacid-insulin co-encapsulated PLGA were investigated with a view 
to increasing the microclimate pH and preventing structural losses and aggregation [36]. 
The antacids assessed were magnesium hydroxide and zinc carbonate. However, short-term 
stability was not reported.  
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1.4.1.3.1.2. PLA 
Polylactides (PLAs) have similar properties to PLGAs but they are more hydrophobic than 
PLGAs and they degrade more slowly due to their crystallinity [37]. Cui et al. [38] reported 
enhanced insulin entrapment efficiency (up to 90%) in PLA and PLGA nanoparticles, where 
insulin was complexed with phosphatidylcholine (SPC) to improve its liposolubility. An 
oral bioavailability of 7.7% relative to subcutaneous injection was obtained. 
1.4.1.3.1.3. PCL 
Another interesting biodegradable polyester polymer is poly-ɛ caprolactone (PCL). 
Compared with PLGA and PLA, PCL is semi‐crystalline, has superior viscoelastic 
properties and possesses easy formability. PCL has the advantage of generating a less 
acidic environment during degradation as compared with PLGA-based polymers [37]. 
Nevertheless, the hydrophobic nature of PCL affects the encapsulation of hydrophilic 
substances, such as peptides, enzymes and other proteins. Damgé et al. [39] prepared 
nanoparticles from a blend of a biodegradable polyester poly (ε-caprolactone) and a 
polycationic non-biodegradable acrylic polymer (Eudragit® RS). These nanoparticles were 
investigated as a carrier for the oral administration of insulin and demonstrated prolonged 
hypoglycaemic effect of insulin in both diabetic and normal rats. The same author loaded 
nanoparticles with regular insulin ((Actrapid, Novo Nordisk) or insulin-Aspart 
((Novorapid). Regular insulin-loaded nanoparticles reduced glycaemia in a dose 
dependent manner with a maximal effect observed with 100 IU/kg. In contrast, insulin 
analogue did not elicit a dose-dependent hypoglycaemic effect. The maximal effect was 
observed with 50 IU/kg insulin while lower (25 IU/kg) and higher doses (100 IU/kg) did 
not show any significant reduction in glycaemia. The authors attributed these 
discrepancies to the saturation of the receptors when the dose of aspart-insulin increases 
to 100 IU/kg [40]. 
1.4.1.3.1.4. PACA 
Poly (alkyl cyanoacrylate) is a biocompatible and biodegradable polymer. It is degraded by 
esterases in biological fluids and produces certain toxic products that will stimulate or 
damage the central nervous system. Thus, this polymer is not authorized for application in 
humans [41]. However, PACA polymers are used to encapsulate insulin using emulsion or 
interfacial polymerization. Damge et al. [42] prepared an insulin-loaded poly (alkyl 
cyanoacrylate) nanocapsule. The oral administration of nanocapsules dispersed in Miglyol 
812 to diabetic rats resulted in a 50% reduction of initial glucose levels from the second hour 
for up to 10-13 days. This effect was shorter (2 days) or absent when the nanocapsules were 
dispersed in water, whether with surface active agents or not. Insulin-loaded poly (ethyl 
cyanoacrylate) nanoparticles were prepared from microemulsions with a different 
microstructure and were administered orally to diabetic rats. A consistent and significant 
hypoglycaemic effect over controls was found for up to 36 h depending upon the type of 
monomer (ethylcyanoacrylate or butyl cyanoacrylate). However, no significant serum 
insulin levels were detectable [43]. 
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1.4.1.3.1.5. Poly (Acrylic acid)  
These are non-degradable polymers with mucoadhesive properties based on acrylic or 
methacrylic acid. Anionic polymers, such as methyl acrylic acid (Eudragit L-100) and methyl 
methacrylate (S-100), have been used to formulate pH sensitive nanocarriers. 
Polymethacrylic acid–chitosan–polyethylene glycol nanoparticles were developed by Pawar 
et al. for the oral delivery of insulin. These nanoparticles displayed excellent binding 
efficiency on mucin from porcine stomach and elicited pH dependent release profiles in 
vitro [44]. The nanoparticles were formed by a complex coacervation method using 
EudragitL100-55 and chitosan of various molecular weights. Insulin release from these 
nanoparticles was pH-dependent [45]. The distribution, transition and bioadhesion of 
insulin-loaded pH-sensitive nanoparticles prepared from EudragitL100-55 and chitosan 
were investigated. The addition of the hydroxypropylmethylcellulose reduced the stomach- 
and intestine-emptying rates and enhanced the adhesion of the nanoparticles to the 
intestinal mucosa [46]. 
1.4.1.3.2. Natural polymers 
The naturally-occurring polymers of particular interest in the oral delivery of insulin are 
either polysaccharides or else proteins. Polysaccharides include chitosan, hyaluronan, 
dextran, cellulose, pullulan, chondroitin sulphate and alginate. Meanwhile, the protencious 
polymers are casein and gelatin. They are nontoxic, biocompatible, biodegradable and 
hydrophilic. The structure of these natural polymers is illustrated in Table 4. Examples of 
the natural polymers used to prepare insulin-loaded nanoparticles and the methods used for 
their fabrication are shown in Table 5.  
1.4.1.3.2.1. Dextran 
Dextran sulphate is an exocellular bacterial polysaccharide consisting of linear 1,6-linked D-
glucopyranose units and branches beginning from α-1,3-linkages with approximately 2.3 
sulphate groups per glucosyl residue. It is a nontoxic, highly water-soluble, biodegradable 
and biocompatible branched negatively charged polyion. A nanoparticle insulin delivery 
system was prepared by the polyelectrolyte complexation of oppositely charged natural 
polymers - dextran sulphate and chitosan in an aqueous solution. These pH sensitive 
nanoparticles released insulin in the intestinal medium [47]. The natural uptake processes of 
the intestine were utilized for the oral delivery of peptides and proteins. Vitamin B12 is an 
example of such carriers and was investigated for delivering different peptides [48]. Due to 
the susceptibility of vitamin B12/peptide conjugate to gastrointestinal degradation, dextran 
nanoparticles were coated with vitamin B12 and used as a carrier for the oral delivery of 
insulin [49]. These nanoparticles were found to be targeted at the systemic circulation 
through vitamin B12-intrinsic factor receptor ligand-mediated endocytosis via ileocytes of 
the intestine [49]. The % pharmacological availability of nanoparticle conjugates containing 
2, 3 and 4% w/w insulin was 1.1, 1.9 and 2.6 times higher, respectively, compared with 
nanoparticles without VB12. 
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Polymer Chemical Structure
PLGA 
 
x = number of units of lactic acid 
y = number of units of glycolic acid 
 
PLA 
Polycapolactone
Ethyl 
cyanoacrylate 
monomer 
Poly (acrylic acid)
Table 2. Chemical Structure of Synthetic Polymers 
1.4.1.3.2.2. Alginate 
Alginate is a naturally occurring polysaccharide obtained from marine brown algae. It is a 
linear copolymer composed of 1,4-linked-β-D-mannuronic acid and α-L-guluronic acid 
residues that gel in the presence of divalent cations. It is a nontoxic and biodegradable 
polyanion that forms polyelectrolyte complexes with polycations, such as chitosan. Insulin-
loaded nanoparticles were prepared by the ionotropic pre-gelation of alginate with calcium 
chloride followed by complexation between alginate and chitosan [50]. The pharmacological 
effect of insulin-loaded nanoparticles was evaluated in diabetic rats. The pharmacological 
availability was 6.8% and 3.4% for the 50 and 100 IU/kg doses, respectively [51]. 
Alginate/chitosan nanoparticles form complexes with cationic β-cyclodextrin polymers. The 
nanoparticles protect insulin against degradation in simulated gastric fluid [52]. Reis et al. 
[53] evaluated nanoparticle systems composed of alginate/chitosan cores coated with 
chitosan-polyethylene glycol-albumin. Albumin was added to prevent protease attacks on 
the insulin and chitosan for its mucoadhesive properties, while PEG served as a nanosphere 
stabilizer to improve the half-live of the insulin and increase the residence time along the 
intestine. Chitosan-PEG-albumin coated nanospheres demonstrated a more than 70% blood 
glucose reduction, increased insulinemia by a factor of seven and significantly improved the 
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response to the glucose oral tolerance test following oral administration to diabetic rats. In 
contrast, nanospheres lacking albumin and PEG in the coating material were ineffective. 
Multilayer nanoparticles consisting of calcium cross-linked alginate, dextran sulphate, 
poloxamer 188, chitosan and an outermost coating of albumin were developed. A 3-factor 3-
level Box–Behnken statistical design was used to optimize the nanoparticle formulation. 
Solutions of 0.20% calcium chloride, 0.04% chitosan and 0.47% albumin constituted the 
optimum formulation of nanoparticles for orally-dosed insulin [54]. The relative 
pharmacological availability and bioavailability were calculated after oral administration of 
50 IU/kg of insulin-loaded multilayered nanoparticles to diabetic rats and were found to be 
11% and 13%, respectively [55]. 
 
Polymer Method of preparation Particle 
size 
(nm) 
Pharmacological 
availability (PA)/ or 
relative bioavailability 
(RBA) 
Ref. 
PGLA Double-emulsion/solvent
evaporation technique 
208 Not calculated 31 
PLGA and 
chitosan 
Water-in oil-in-water 
solvent evaporation 
technique 
150 PA: 10.5% 34 
PLGA, Eudragit® 
RS (RS) and 
Hydroxypropyl 
methylcellulose 
phthalate 
Multiple emulsions 
solvent evaporation 
technique. 
285 PA: 9.2% 35 
PCL and 
Eudragit® RS 
Double emulsion method 331 RBA: 13% 39 
Table 3. Synthetic polymers used for the preparation of nanoparticles and the methods used for their 
fabrication 
Polymer Chemical Structure
Dextran 
Alginate 
 
Chitosan 
Table 4. Chemical Structure of Natural Polymers 
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As illustrated in Table 5, the most widely explored polymer is chitosan. This is because of its 
favourable biological properties, safety, low cost and easy modification. Compared to 
synthetic polymers, the degradation products of chitosan are amino sugars, which are easily 
metabolized by the body. Therefore, there is no concern of an acidic microclimate being 
generated by chitosan particles [56]. 
 
Polymer Method of preparation Particle 
size 
(nm) 
Pharmacological 
Availability (PA)/ or 
Relative 
bioavailability 
(RBA) 
Ref. 
Chitosan and Poly 
(γ-glutamic acid) 
Ionic-gelation method: the nanoparticles 
were freeze-dried and placed in enteric-
coated capsules 
232.9  RBA: approximately 
20%. 
70 
Chitosan and Poly 
(γ-glutamic acid) 
A penetration enhancer (DTPA) was 
covalently conjugated on poly (g-
glutamicacid) followed by ionic-gelation 
with chitosan  
246.6  RBA: approximately 
20% 
71 
Chitosan, 
Alginate, Dextran, 
Poloxamer, and 
BSA 
Ionotropic pre-gelation followed by 
polyelectrolyte complexation 
396  RBA: 13.2±2.9 52 
Dextran Cross-linking of emulsion to prepare 
dextran nanoparticles. The surface was 
modified with succinic anhydride and 
conjugated with amino VB12 derivatives 
of the carbamate linkage. 
160-250  PA: 26.5 49 
Table 5. Natural polymers used for the preparation of nanoparticles and the methods used for their 
fabrication 
What is Chitosan? 
Chitosan is a linear copolymer consisting of ß (1-4)-linked 2-amino-2-deoxy–D-glucose (D-
glucosamine) and 2-acetamido-2-deoxy-D-glucose (N-acetyl-D-glucosamine) units (Table 4). 
It is obtained by the alkaline N-deacetylation of chitin, which is the primary structural 
component of the outer skeletons of crustaceans. Chitosan is a weak poly base due to the 
large quantities of amino groups on its chain [57]. Both high molecular weight (HMWC) and 
low molecular weight chitosans (LMWC) are available. The latter were obtained by the 
depolymerization of HMWC. This can be carried out by enzymatic [58,59], physical [60, 61] 
or chemical methods [62, 63]. Another important property of chitosan is the degree of 
deacetylation (DDA), defined in terms of the percentage of primary amino groups in the 
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polymer backbone. The properties of chitosan and its biological role are dependent on the 
DDA and M.wt [64]. Chitosan dissolves easily at low pH due to the protonation of the 
amino groups, while it is insoluble at higher pH ranges since the amino groups become 
deprotonated, as the pH approach the pKa of chitosan (6-6.5). The solubility of chitosan 
depends upon the molecular weight and DDA. 
Chitosan nanoparticles have been prepared using ionotropic gelation with tripolyphosphate 
or even simply polyelectrolyte complexation between insulin and chitosan. The interaction 
of chitosan and polyanions leads to the spontaneous formation of nanoparticles in an 
aqueous environment without the need for heating or the use of organic solvents [65]. In 
addition, to ease of preparation under mild conditions, a high level of drug entrapment can 
be achieved so that the protein secondary structure and biological activity is preserved [66]. 
Insulin-loaded chitosan nanoparticles were prepared by the ionotropic gelation of chitosan 
with tripolyphosphate anions [67]. These nanoparticles were effective at lowering the serum 
glucose level of streptozotocin-induced diabetic rats when administered orally at insulin 
doses of 50 U/kg and/or 100 U/kg. However, they dissociate easily in acidic gastric 
conditions. To protect insulin from harsh GIT conditions, chitosan nanoparticles were 
formulated with an enteric coating polymer - hydroxypropyl methylcellulose phthalate 
(HPMCP) - and evaluated for the oral delivery of insulin. HPMCP-chitosan nanoparticles 
showed a 2.8-fold increase in their hypoglycaemic effect when compared with chitosan 
nanoparticles without HPMCP [68]. Self-assembled nanoparticles were developed by 
mixing the anionic poly-γ-glutamic acid (γ-PGA) solution with the cationic chitosan 
solution in the presence of MgSO4 and sodium tripolyphosphate (TPP). TPP and sulphate 
salts were physically added to crosslink chitosan by ionic gelation, while physical gelation 
may occur between Mg+ and the carboxylate ions on γ-PGA via an electrostatic interaction. 
Chitosan-γ-PGA nanoparticles remained intact within the pH range of 2.0–7.2; however, at 
lower pH values they disintegrated. The pharmacodynamics and pharmacokinetics of 
insulin were evaluated in a diabetic rat model and the relative bioavailability was 15% [69]. 
For the further enhancement of bioavailability, two approaches were investigated: in the 
first, chitosan- γ-PGA nanoparticles were freeze-dried and placed in an enteric-coated 
capsule, while in the second, a penetration enhancer - diethylene triamine pentaacetic acid 
(DTPA) - was added. In both cases the bioavailability was approximately 20% [70,71]. 
The problem of the low solubility of chitosan in the neutral environment of the intestine was 
solved by synthesis of a partially quaternized derivative of chitosan - Trimethyl chitosan 
(TMC). TMC has good solubility and a permeation enhancing effect [72]. The targeting of 
trimethyl chitosan chloride to goblet cells was achieved through modification with a 
CSKSSDYQC (CSK) targeting peptide. The significant internalization of insulin via clathrin- 
and caveolae-mediated endocytosis on goblet cell-like HT29-MTX cells results in a better 
hypoglycaemic effect with a 1.5-fold higher relative bioavailability compared with 
unmodified TMC nanoparticles [73]. Trimethyl chitosan-cysteine conjugate and N-(2-
hydroxyl) propyl-3-trimethyl ammonium chitosan were synthesized and demonstrated high 
mucoadhesion capability compared with TMC/insulin nanoparticles or native chitosan [74, 
75]. Quaternized derivatives of chitosan have a high positive charge, which can easily 
 
Oral Delivery of Insulin: Novel Approaches 293 
interact with negatively-charged blood corpuscles, resulting in haemolysis and toxicity [76]. 
To overcome these problems, chitosan derivatives were modified with polyethylene glycol 
to reduce the interaction between the cationic polymers and cell membranes [77]. Chitosan 
was also modified with hydrophobic fatty acids, such as anacardic acid. Anacardoylated 
chitosan spontaneously formed nanoparticles in an aqueous insulin solution that sustained 
the release of insulin in the intestinal environment [78]. 
1.4.1.4. Mechanisms of the absorption of nanoparticles 
The absorption of the nanoparticles was thoroughly reviewed by des Rieux [8]. A particle can 
traverse the intestinal epithelium by the paracellular (between cells) or transcellular route 
(through the cells). The transcellular route is the most common. With the transcellular 
transport of nanoparticles, the particles are taken up by cells through the endocytic process - 
which takes place at the cell apical membrane - transported through the cells and released at 
the basolateral pole. Two types of intestinal cells are important in nanoparticle transcytosis: 
the enterocytes lining the gastrointestinal tract and the M cells mainly located in Peyer’s 
patches. The uptake of nanoparticles takes place by one of three endocytotic mechanisms: 
pinocytosis, macropinocytosis or clathrin-mediated endocytosis. Clathrin vesicles are for 
particles smaller than 150 nm while phagocytosis is for particulate matters of up to several 
µm. The uptake of particles, microorganisms and macromolecules by M cells occurs by fluid 
phase endocytosis, adsorptive endocytosis and phagocytosis [8]. 
1.4.2. Lipid-based systems 
Lipid-based delivery systems (LDS) range from simple oil solutions to complex mixtures of 
oils, surfactants, cosurfactants and cosolvents [79]. The bioavailability of several peptides 
was improved when incorporated into LDS - e.g., cyclosporine (Neoral®). The enhancement 
in absorption was attributed to an increase in membrane permeability, the inhibition of 
efflux transporters, a reduction in cytochrome P450 enzymes, an increase in chylomicron 
production and lymphatic transport [80]. 
1.4.2.1. Types 
The LDS investigated for the delivery of insulin are: multiple emulsions, microemulsions 
and solid in-oil-in water systems. 
1.4.2.1.1. Water-in-oil-in-water 
A water-in-oil-in-water (W/O/W) emulsion has been proposed to protect peptides against 
proteolysis and enhance their absorption. Multiple emulsions containing unsaturated fatty 
acids (oleic acid, linoleic acid and linolenic acid) have been reported to enhance the ileal and 
colonic absorption of insulin without tissue damage [81]. The transport enhancement of the 
W/O/W emulsion prepared with octanoic acid triacylglycerol was found to be affected by 
the size of oil droplets. When the oil-droplet median was 2.3 µm, an earlier hypoglycaemic 
response was observed compared with a multiple emulsion, having a diameter of 3.8 µm. In 
contrast, the emulsion with a diameter of 0.7 µm exhibited no effect [82].  
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1.4.2.1.2. Microemulsions 
Microemulsions are clear, stable, isotropic mixtures of oil, water and surfactant, frequently 
in combination with a cosurfactant [83]. The average particle size of microemulsions falls in 
the range of 5-100 nm; they are polydispersed in nature and the polydispersity decreases 
with decreasing particle size [84]. Insulin-loaded microemulsions were developed using 
didodecyldimethylammonium bromide as the surfactant, propylene glycol as the co-
surfactant, triacetin as the oil phase and insulin solution as the aqueous phase. These 
microemulsions displayed a 10-fold enhancement in bioavailability compared with a plain 
insulin solution administered orally to healthy rats [85]. The improved oral bioavailability of 
the w/o microemulsion system was also shown for a lecithin-based microemulsion of rh-
insulin [86]. On the other hand, Kraeling and Ritschel [87] found that the oral 
pharmacological availability of insulin microemulsions as compared with intravenous 
insulin in beagle dogs was 2.1%, which further increased to 6.4% with the encapsulation of 
gelled microemulsions in hard gelatine capsules along with the protease inhibitor aprotinin 
and coating of the capsules for colonic release [87]. The improved oral delivery of insulin 
from a microemulsion system was also demonstrated by others [88]. A stable self-
emulsifying formulation for the oral delivery of insulin was developed by Ma et al. [89]. It is 
composed of two non-ionic surfactants (polyethylene glycol-8-glycol octanoate/decanoate 
and polyglycerol-3 oleate). In diabetic beagle dogs, the bioavailability of this formulation 
was up to 15.2% at a dose of 2.5 IU/kg in comparison with the hypoglycaemic effect of 
native insulin (0.5 IU/kg) delivered by subcutaneous injection. 
1.4.2.1.3. Solid-in-oil-in water (S/O/W) emulsions  
S/O/W emulsions were also developed for the delivery of insulin whereby insulin was 
converted into a lipophilic complex by coating with surfactant molecules and dispersed in 
an oil phase of oil in a water emulsion to form the S/O/W emulsion [90]. The stability of this 
system was enhanced by lyophilization [91]. 
1.4.2.2. Mechanism of the absorption of lipid-based formulations  
Suggested mechanisms of intestinal drug absorption, using lipid-based formulations 
include: an increase in membrane fluidity facilitating transcellular absorption, the opening 
of the tight junctions to allow paracellular transport (mainly relevant for ionized drugs or 
hydrophilic macromolecules), the inhibition of P-glycoprotein and/or cytochrome P450 to 
increase intracellular concentration and residence time, and the stimulation of lipoprotein/ 
chylomicron production [92]. 
2. Chitosan-fatty acid systems 
2.1. Rationale 
Chitosan nanoparticles prepared by ionotropic gelation or polyelectrolyte complexation 
dissociate easily in an acidic medium. This might be related to the fact that both insulin and 
chitosan have net positive charges at pH 1.2, that the columbic repulsive forces lead to the 
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dissociation of the complex and that the free insulin is subjected to degradation. For 
example, nanoparticles prepared from chitosan and poly (γ-glutamic acid) became unstable 
at pH 1.2 and broke apart [93] and nanoparticles composed of chitosan and 
tripolyphosphate rendered the protein more susceptible to acid and enzymatic hydrolysis 
[94]. In the present investigation, we benefited from the advantages of polyelectrolyte 
complexation between chitosan and insulin, its formulation in an aqueous environment 
without the need for heat or an organic solvent, and the solution of the shortcomings of 
burst release by the dispersion of nanoparticles in an oily phase. The oily vehicle was 
intended to reduce proteolytic degradation and improve absorption [95, 96]. In addition, the 
free chitosan amine groups may interact with any adjacent carboxylic acid groups of oleic 
acid, forming a protective hydrophobic coating layer at the surface of the dispersed phase, 
which may enhance stability in the GIT and promote lymphatic uptake. The particle size of 
the chitosan-oleic system is above 1 µm, due to the interaction. The reduction of the particle 
size of chitosan-oleic acid emulsion to nanosize was achieved by high pressure 
homogenization or else by the addition of surfactants. PEG-8 caprylic/capric glycerides 
(Labrasol) and polyglyceryl-6 dioleate were selected as surfactant and cosurfactant, 
respectively. Chitosan-insulin nanoparticles were solubilized in the inverted micelles. 
Chitosan plays an important role - as a matrix for nanoparticles and stabilizers of inverted 
micelles. In a previous work [97], we demonstrated the role of chitosan in the reduction of 
particle size of the w/o emulsion containing Labrasol, plurol oleique and oleic acid. This was 
attributed to the interaction of amine groups of chitosan with the surfactant-cosurfactant 
aggregates, resulting in the formation of a closer packing of surfactants at the interface, 
which leads to a reduction in particle size. This effect is more pronounced in 1:1 
surfactant:cosurfactant rather than in 4:1 systems. Insulin is a water soluble protein that will 
be located inside the water droplets. Chitosan will be partly fixed near the surfactant head 
groups with the rest of it inside the water droplet. Interactions between chitosan, surfactants 
and insulin resulted in smaller microemulsion sizes [97]. Moreover, low molecular weight 
chitosans were chosen to prepare the nanoparticles, since their intestinal absorption is 
known to be significantly better than the high molecular weight candidates and showed a 
negligible cytotoxic effect on the Caco-2 cells [98]. 
The potential of chitosan-fatty acid or chitosan-fatty acid derivative nanoparticles as oral 
delivery carriers of insulin was investigated systematically.  
2.2. Chitosan-fatty acid nanocarriers’ development 
Detailed descriptions of the compositions and preparation methods can be found in the 
relevant patents [99, 100]. Low molecular weight chitosans were obtained by the 
depolymerization of high molecular weight chitosan using 2 M hydrochloric acid. The 
resulting fractions were characterized by Fourier transformed infrared spectroscopy (FTIR), 
differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), nuclear magnetic 
resonance (NMR) and dynamic light scattering (DLS). The polyelectrolyte complexation 
method was utilized to prepare insulin-chitosan nanocomplexes. Chitosan was dissolved in 
deionized water and its pH was adjusted to 5.5 using 0.2 M NaOH. rh-insulin powder was 
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dissolved in 0.1 M HCl, followed by the addition of 1M Tris (hydroxymethyl)-
aminomethane buffer pH 7. Chitosan-insulin complexes were prepared by adding chitosan 
solution to an equal volume of insulin solution in a glass vial under gentle magnetic stirring, 
and incubating for a further 15 minutes at room temperature. The parameters affecting the 
encapsulation efficiency were investigated (final pH of the complex, molecular weight of 
chitosan, DDA of chitosan, initial concentration of chitosan and insulin, and chitosan: 
insulin ratio). A phase diagram was constructed and the results were used as guidance to 
select the suitable percentages of surfactants, oil and aqueous phases suitable for the 
nanoparticle dispersion system. The nanoparticle dispersion system was prepared by 
mixing two phases - the aqueous phase and the oily phase. The oily phase consists of 
Labrasol® and plurol oleique® at a fixed weight (1/1) ratio and oleic acid. The aqueous 
phase composed of a chitosan-insulin complex. To prepare the dispersion system, 50 µl of 
the aqueous phase was added to 2.5 g of the oily phase during mixing with a vortex mixer 
(VELP Scientifica, Europe) for 1 min. at room temperature (25 oC). The preparation was 
characterized: viscosity, particle size, morphology and encapsulation efficiency were all 
determined. The chemical and immunological stabilities of insulin after entrapment into 
nanoparticles were studied. The suitability of the preparation to preserve insulin activity, to 
withstand gut enzymes and to maintain the stability of insulin upon storage was investigated 
[101]. The hypoglycaemic effect of the preparation after oral administration to streptozotocin-
diabetic rats was evaluated. The parameters that influence the pharmacological availability 
were characterized. The bioavailability of the preparation versus subcutaneous injection was 
calculated together with the pharmacokinetic parameters. Moreover, human studies were 
conducted where twenty-five healthy volunteers participated in five studies using a two-
phase, two-sequence crossover design with a washout period of one day [102]. Other 
chitosan fatty acid systems were also formulated, for example chitosan sodium lauryl 
sulphate nanoparticles [103] and chitosan-oleic acid nanoemulsion (particle size reduced by 
a high pressure homogenizer) and their hypoglycaemic effects were evaluated and 
compared to the chitosan-oleic acid-surfactants system. 
2.3. Results and discussion 
2.3.1. Depolymerization and characterization of chitosan 
Most commercially available chitosans possess quite large M.wts. LMWCs are better 
amenable for a wide variety of biomedical applications due to their solubility in water [104-
106]. In addition, chitooligomers were found to be non-mutagenic and non-genotoxic when 
orally administered to mice [107]. To generate low molecular weight chitosans from high 
molecular weight candidates, hydrolysis by hydrochloric acid was adopted due to its 
practicability and reproducibility. IR spectrum spectroscopy demonstrated that there was no 
structure change during depolymerization. DDA was determined by NMR and it was about 
99%. [101]. The solubility of chitosan increased with decreasing molecular weight. Chitosan 
has a positive zeta potential and its value is affected by the pH, molecular weight, DDA and 
concentration [108]. LMWCs with an average molecular weight of 13 KDa and DDA ~ 99% 
were used for further studies.  
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2.3.2. Chitosan-insulin polyelectrolyte complexes (PECs) 
Insulin was first complexed with chitosan through the interaction of negatively charged 
insulin with positively charged chitosan to form PEC before incorporation into the oily 
vehicle. This is because chitosan has many beneficial effects, such as penetration 
enhancement. Chitosan was also found to stabilize insulin when incubated at 50 ± 1 °C 
while shaking at 100 strokes/min in a water bath [101]. As shown in Figure 3, the insulin 
solution was almost degraded while the chitosan-insulin complex protected the insulin 
from degradation for at least 24 h. In addition, chitosan has a role in protecting insulin 
from those enzymes present in the small intestine. This was reflected in the partial 
protection of insulin from pancreatin, as depicted in Figure 4, and the protection increases 
with the increase of the chitosan ratio. Moreover, chitosan may also protect insulin from 
destabilization at the oil/water interface when the PEC was dispersed in the oily vehicle. 
The PEC formation process is influenced by a variety of parameters, including the system 
pH, chitosan molecular weight and DDA. The most important factor appears to be the 
system pH [101].  
 
Figure 3. Effect of the temperature and shaking on the stability of the insulin 
 
Figure 4. Effect of the chitosan:insulin ratio on the pancreatic degradation of insulin 
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2.3.3. Oily nanosystem preparation  
Chitosan-insulin PECs were solubilized in an oily vehicle composed of a surfactant Labrasol, 
cosurfactant Plurol Oleique and an oily vehicle oleic acid. We attempted to formulate an oral 
insulin delivery system that combined the advantages of nanoencapsulation and the use of an 
oily vehicle. The nanoparticles were expected to translocate the intestinal epithelium, while 
the oily vehicle was intended to reduce proteolytic degradation and improve permeability 
[109, 110]. In addition, Labrasol and oleic acid are known penetration enhancers [111, 112]. 
Our expectation is that part of the chitosan will rest inside the water droplet of the inverted 
micelles where it forms PEC with insulin while the other part projecting near the surfactant 
head groups where it interacts with surfactants stabilizes the w/o microemulsion and resulted 
in smaller microemulsion sizes [97]. Chitosan at pH 6 will also interact with oleic acid to coat 
the particles with a hydrophobic layer. This interaction was studied by molecular mechanics, 
as illustrated in Figure 5. The structure of chitosan 13 KDa, oleic acid and chitosan-oleic acid  
 
Figure 5. a. Top view (A) and side view of chitosan (B); b. The computed molecular geometries of oleic 
acid; c. Top view (A) and side view of the chitosan-oleic acid complex 
(a)
(b)
(c)
A
B
A B
 
Oral Delivery of Insulin: Novel Approaches 299 
complex, which were built up in Hyperchem®, was shown in Figures 5.a, b and c, respectively. 
The conformation of individual chitosan and oleic acid was the same as the complex. 
It is obvious that the outer structure of the complex was hydrophobic due to presence of 
oleic acid while chitosan was embedded inside the structure. This is consistent with the 
immiscibility of the complex with water. The binding energy of the resulting chitosan oleic 
acid complex is calculated according to the following equation:  
( )   = − +E binding E complex Eoleate Echitosan  
 . ;   . ;   . ;     .  / .= − = = = −complex oleic chitosanE 539 94 E 2131 64 E 4526 58 E binding 7198 2 kcal mol  
The value of the binding energy suggested a high degree of interaction between chitosan 
and oleic acid. The chitosan-oleic acid interaction was also studied using statistical design 
[108]. The effects of three formulation variables (the aqueous chitosan solution to oleic acid 
ratio, the chitosan molecular weight, and the degree of deacetylation of chitosan) on the 
viscosity of the system and the length of the emulsified layer (%) were studied in a 
conventional 23 factorial design. It was found that chitosan-oleic acid interaction is 
significantly influenced by pH. At a pH of around 6.5, chitosan is almost 50% ionized (pKa 
NH3/NH2 ~ 6.5) and the ionized amine groups in chitosan will interact with the carboxylate 
ion of oleic acid. However, at pH 1.5, chitosan will be available as chitosan hydrochloride, 
and so no interaction was observed. 50% oleic acid and 50% chitosan aqueous solution (2%) 
at different pH were mixed and their viscosities were determined, as depicted in Figure 6. A 
sharp increase in viscosity was noticed when the pH of chitosan was ≥ 5.5. This indicates 
that the rheological properties of this dispersion were notably influenced by other factors - 
apart from the disperse phase volume fraction - such as the interaction between chitosan 
and oleic acid. These results were consistent with the surface tension measurements of the 
chitosan-oleic acid system [97].  
 
Figure 6. The effect of the pH of chitosan on the viscosity of oleic acid chitosan dispersions 
2.3.4. Oily nanosystem characterization 
The mean particle size was determined by dynamic light scattering - it was 111 ± 6.9 nm - 
and showed a unimodal particle size distribution. The particle size is affected by the 
molecular weight of chitosan, as shown in Table 6. An increase in the molecular weight of 
the chitosan polymer led to an increase in the dispersed phase particle size. The particles’ 
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shapes were assessed by a transmission electron microscope (TEM) and it was spherical, as 
depicted in Figure 7. The viscosity of the nanosystem was measured by a Vibro viscometer - 
it was 52.25 ± 2.6 mPa s. Neither the particle size nor the viscosity of the nanosystem 
changed upon storage at 4 or 25 ºC for one month, indicating the physical stability of the 
nanosystem. The preparation procedure is mild and the insulin is chemically and 
immunologically stable, as illustrated by RP-HPLC and ELISA, respectively. About 90% of 
the insulin was recovered from the preparation after incubation with pepsin, indicating the 
protective ability of the preparation for insulin under conditions simulating the gastric 
environment [97]. In addition, short term chemical stability demonstrates that the chemical 
stability of the insulin was maintained for at least 30 days of storage at 4 and 25 °C, 
according to the HPLC method. Moreover, the biological activity was reserved after one 
month at storage temperatures of 4 and 25 ºC. 
 
Chitosan 
M.wt (KDa) 
Mean diameter 
(nm) ± SD 
3 79 ± 2.5
13 111 ± 6.9
30 205 ± 2.6
Table 6. The mean diameter of the oily nanosystem prepared from chitosans with different molecular 
weights  
 
Figure 7. TEM image of the oily nanosystem 
2.3.5. In vivo studies 
The preliminary screening of the biological activity of nanoparticles prepared from different 
grades of chitosan (different molecular weights and DDA) and administered orally to STZ 
diabetic rats revealed a maximum effect with nanoparticles prepared from chitosan with a 
molecular weight of 13 KDa and DDA~ 99%. Figure 8 illustrates changes in the plasma 
glucose levels after the oral administration of the nanoparticles prepared from chitosan with 
a molecular weight of 13 KDa and DDA 99%. As expected, the insulin oral solution showed 
no hypoglycaemic effect compared to the control group (P > 0.05). In contrast, the blood 
glucose levels of the rats decreased remarkably after the oral administration of insulin-
loaded nanosystem, achieving a significant decrease at 3 h when compared with the control 
group (P< 0.05). More interestingly, the hypoglycaemic effect was maintained without 
recovery at the baseline for 12 h. A pharmacological availability value of 29% was obtained 
for the dose 5 IU/kg. An explanation of this positive behaviour of the oily nanosystem could 
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be put forward in terms of the demonstrated ability of oily preparations to make the 
entrapped insulin more stable and protect it from degradation in the harsh conditions of the 
gastrointestinal tract as well as enhance its intestinal absorption.  
 
Figure 8. Changes in blood glucose level versus time profiles after a single oral administration of the 
oily dispersion of chitosan-insulin nanoparticles given at a dose level 5 IU/Kg (■) to STZ-diabetic rats 
compared to a free insulin solution given orally (50 IU/Kg) as a control group (∆) and a subcutaneous 
injection of a free insulin solution (1IU/Kg) (▲). The results are expressed as the mean ± S.E.M (n = 12 per 
group) 
A concomitant increase in plasma insulin levels was observed after the oral administration of 
the 5 IU/kg of insulin-loaded oily nanosystem to diabetic rats, as depicted in Figure 9. The 
pharmacokinetic parameters were determined based on the insulin concentration plasma 
profiles of Figure 9, as shown in Table 7. The subcutaneous injection group exhibited a rapid 
increase in serum rh-insulin concentration up to 279.2 µIU/ml over 30 min of administration. 
Meanwhile, the intragastric administration of 5 IU/kg of nanoparticles exhibited slower 
absorption and sustained elimination, reaching a maximum after 2 h (102.22 µIU/ml). 
Moreover, the serum rh-insulin levels of the nanoparticle group were significantly different 
from that of the control group (P < 0.001). The AUC0-12 of orally administered nanoparticles 
was 664.99 µg hr/ml for the 5 IU/kg dose and 626.02 µg hr/ml for the 1 IU/kg subcutaneous 
rh-insulin dose. The corresponding relative bioavailability was calculated to be 21.24% [108]. 
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These results clearly show that rh-insulin absorption was markedly enhanced by the 
nanoparticles dispersed in oily vehicle. As a proof of concept, early clinical trials have been 
performed by Badwan et al. [102]. The pharmacokinetic, pharmacodynamic and absorption 
kinetics of insulin-loaded oily nanosystem preparations of different particle sizes (57-220 
nm) were compared with those of subcutaneous formulation in 25 healthy individuals using 
a euglycaemic clamp technique. The dose used was either 1, 2 or 3 IU/Kg. The effective 
permeability ratio (Peff*) was higher for preparations with a particle size of 57 nm than for 
those with a larger particle size. The preparation with the lowest particle size also exhibited 
the highest ratio in the dimensional analysis of the glucose infusion rate as a 
pharmacodynamic effect, while the other insulin formulations that were tested showed 
similar ratio profiles. The calculated intestinal permeability coefficients (×10–4) of the insulin 
best test and reference formulations were 0.084 and 0.179 cm/sec respectively. The total 
fraction of the insulin dose absorbed (Fa) for the test and reference products were 3.0% and 
19% respectively. From these small studies, it was concluded that oral insulin bioavailability 
is promising for the development of oral insulin products. 
 
Figure 9. Insulin plasma levels profile after a single oral administration of the oily dispersion of 
chitosan-insulin nanoparticles (5 IU/Kg) (■ ) in fasted diabetic rats compared to the subcutaneous 
injection of free insulin (1 IU/Kg) (▲) and an oral insulin solution (50 IU/kg) as a control (▲). The results 
are expressed as the average of the three independent experiments (n = 18) 
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Preparation Cmax
[ µg/ml]
Tmax [hr] MRT [hr] AUC0-12
[µg hr/ml]
F % 
S.C injection
(1 IU/kg) 
279.19 0.5 626.02  
Oral formula
(5 IU/kg) 
102.22
 
2 6.72 664.99 21.24%. 
 
Table 7. Pharmacokinetic parameters derived from the plasma level vs. the time profile for insulin 
Other chitosan fatty-acid systems were also developed and compared to the above mentioned 
system. For example, chitosan-sodium lauryl sulphate nanoparticles dispersed in an aqueous 
vehicle elicited a pharmacological response after oral administration [103]. However, the 
pharmacological availability was poor - 1.1% versus 29% for nanoparticles dispersed in an 
oily vehicle. Another system was developed by dispersing PEC in oleic acid and the particle 
size was reduced using a high pressure homogenizer. The oral administration of this 
preparation resulted in a pronounced effect (P < 0.001) after 12 h of administration and the 
effect was sustained for 24 h (Figure 10). This indicates that chitosan-oleic acid nanoparticles 
were slowly absorbed in comparison with the preparation containing surfactants. This may 
be due to the permeation enhancing effect of surfactants [108] 
 
Figure 10. Changes in blood glucose level versus time profiles after a single oral administration of an 
oily dispersion of a chitosan-insulin oily nanosystem containing surfactant given at a dose level of 5 
IU/Kg (■) to STZ-diabetic rats compared to a chitosan-insulin oily nanosystem without surfactant (▲). 
The control was given a placebo (a formula containing all excipient) (x). The results are expressed as the 
mean ± S.E.M (n = 12 per group) 
In conclusion, the use of the combination strategy of nanoencapsulation and an oily vehicle 
has shown considerable improvement in insulin delivery along the following lines:  
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1) A significant hypoglycaemic action with a maximum pharmacological availability of 
29.0% was obtained; 2) The relative bioavailability was 21.2%; 3) The antidiabetic activity 
was prolonged for many hours; 4) The insulin in the preparation was chemically and 
biologically stable for a period of one month at storage temperatures of 4 °C and 25 °C. 5). 
The system could be considered as a platform technology for the delivery of other peptides, 
such as calcitonin. 
3. Oral insulin formulations in clinics  
Oral systems in different clinical phases and the companies who have invested on them 
were listed in Table 8. The modification of proteins’ structures by the attachment of proper 
moieties which alter their biopharmaceutical properties have been investigated by Biocon 
(Bangalore, India) and Nobex Corporation (Research Triangle Park, NC, USA). Nobex 
developed an orally active amphiphilic human insulin analogue, methoxy (polyethylene 
glycol) hexanoyl human recombinant insulin. Biological activity is retained and this 
compound is readily absorbed from the gastrointestinal tract. The effect of a single oral dose 
of hexyl-insulin monoconjugate 2 (HIM2) on the rate of whole-body glucose disposal (Rd) 
and endogenous glucose production (EGP) was investigated in healthy non-diabetic subjects 
using a euglycaemic clamp technique. Oral HIM2 suppresses EGP and increases tissue Rd in 
a dose-dependent manner. The effects of HIM2 on EGP and Rd persisted for 240 min. In 
patients with type 1 diabetes mellitus, a statistically significant effect of HIM2 on glucose 
excursion was observed [113]. The further development of the product was abandoned by 
the company. Biocon modified the hexyl insulin monoconjugate 2 (HIM2) developed by the 
Nobex Corporation. Conjugation with poly (ethylene glycol) improves the protein 
solubility, stability from enzymatic degradation and intestinal absorption [114]. The 
modified insulin (IN-105) was formulated as tablets and has a short duration of action (1.5-2 
h). It was found that IN-105 reduced postprandial glucose excursion by 2 h in a dose-
dependent manner and that it was readily tolerated by patients [115]. However, in Phase III 
studies, IN-105 did not meet the target of lowering the level of glycated haemoglobin by 
0.7% compared to a placebo, as announced by the company. The level of glycated 
haemoglobin in the body is an indication of the effectiveness of a drug in controlling blood 
sugar levels. In contrast, the noncovalent interaction of macromolecules with small 
hydrophobic organic compounds, SNAC (n-(8-[2-hydroxybenzoyl]-amino) caprylic acid) 
and 5-CNAC (N-(5-chlorosalicyloyl)-8-aminocaprylic acid), was the technology developed 
by Emisphere’s Eligen™. As a result of this interaction, the lipophilicity and absorption of 
the macromolecules increases and this is reflected in the rapid onset of action (about 10 
minutes). Emisphere’s oral insulin product was well tolerated and improved both glycaemic 
control and insulin sensitivity. However, a high dose (40 mg/day) is needed to decrease 
HbA1c significantly after 3 months of therapy [116]. ORMD 0801 is a capsule formulation of 
insulin developed by Oramed Pharmaceuticals (USA). An omega-3 fatty acid (carrier), a 
soya bean trypsin inhibitor (protease inhibitor) and sodium EDTA (absorption enhancer) 
were selected as adjuvants to protect the insulin from the harsh environment of the 
gastrointestinal tract and enhance its transport across the intestinal mucosa. ORMD is an 
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intermediate insulin product with a duration of action of 5-6 h. This product demonstrated 
improved absorption, as indicated by a 28% increase in post-prandial serum insulin and it is 
well tolerated by patients [117]. However, the onset of action is delayed by 2 h, which may 
be due to the enteric coating of the capsules. Another capsule formulation (Capsulin) was 
developed by Diabetology (Jersey, UK). The capsule contains a mixture of penetration 
enhancers and solubilizers which are generally considered to be safe. The administration of 
the oral insulin Capsulin preparation to sixteen persons with type 2 diabetes demonstrated a 
significant hypoglycaemic action over a period of 6 h and was associated with only a small 
increase in circulating plasma insulin concentrations. Significant falls in HbA1c, weight and 
triglycerides were also observed [118]. 
 
Technology Example Company Current 
status 
Ref 
Chemical 
modification 
Hexyl-insulin monoconjugate-2 
(HIM2) 
Nobex corporation Phase II [113] 
Chemical 
modification 
IN-105 Biocon Phase III [115] 
Delivery agent Sodium N-[8-(2-hydroxybenzoyl) 
amino] carpylate (SNAC) 
Emisphere Phase II [116] 
Soft-gel capsule with 
enhancers 
Oramed insulin capsule Oramed 
Pharmaceuticals (USA).
Phase II [117] 
Absorption enhancers 
(AxcessTM delivery 
technology) 
CapsulinTM Diabetology (Jersey, 
UK) 
Phase II [118] 
Table 8. Systems currently being studied for the oral delivery of insulin 
4. Conclusions and prospects for further investigations 
Oral delivery is a physiological route for insulin administration. Improved disease 
management, the enhancement of patient compliance and the reduction of long-term 
complications of diabetes could be achieved by oral application. However, the challenges for 
developing oral insulin dosage forms are significant. A number of reports have appeared in 
the literature seeking to enhance insulin delivery via the oral route; however, the 
bioavailability in humans has not exceeded 10%. Most systems evaluated the 
pharmacodynamics and pharmacokinetics of oral insulin preparations on animal models. 
However, a few reports studied absorption mechanisms. The absorption of insulin is the 
major obstacle. Therefore, more focus should be directed on studying the very small details 
of absorption, especially with the development of many instrumental technologies that will 
help in this area. Nanotechnology will contribute largely to the success of oral insulin 
delivery. The investigators should plan to search for safer, simpler and scalable methods 
using biologically acceptable polymers. Nowadays, researchers from both academia and 
industrial fields work on oral insulin. With these efforts, the dream of oral insulin will 
become real in the near future. 
 
Recent Advances in Novel Drug Carrier Systems 306 
Nomenclature 
Da Dalton 
KDa Kilodalton 
HDV Hepatic directed vesicles 
PCL poly ɛ -caprolactone 
PLGA Poly (lactic-co-glycolic acid) 
PL 
PACA 
Polylactides 
Poly (alkyl cyanoacrylate)   
PEG Polyethylene glycol 
LMWC Low molecular weight chitosan 
HMWC High molecular weight chitosan 
DDA Degree of deacetylation 
M.wt Molecular weight 
HPMCP Hydroxypropylmethylcellulose phthalate 
γ-PGA poly-γ-glutamic acid 
TPP Tripolyphosphate 
TMC Trimethyl chitosan 
LDS 
SLN 
GIT 
Lipid-based delivery systems 
Solid lipid nanoparticles 
Gastrointestinal tract 
rh-insulin 
WGA 
Recombinant human insulin 
Wheat germ agglutinin binds 
FTIR Fourier Transformed Infrared Spectroscopy 
DSC Differential Scanning Calorimetry 
XRPD X-Ray Powder Diffraction 
NMR Nuclear magnetic resonance 
DLS Dynamic light scattering 
RP-HPLC Reversed-phase high performance liquid chromatography 
ELISA Enzyme-linked immunosorbent assay 
TEM Transmission electron microscope 
PECs Protein Polyelectrolyte Complexes 
AE Association efficiency 
SLS Sodium lauryl sulphate 
LDS 
BSA 
Lipid-based delivery systems 
Bovine serum albumin 
SGF Simulated gastric fluid 
SIF Simulated intestinal fluid 
W/O Water in oil 
O/W Oil in water 
W/O/W Water-in-oil-in-water 
S/O/W Solid-in-oil-in water 
RSD Relative standard deviation 
 
Oral Delivery of Insulin: Novel Approaches 307 
s.c. Subcutaneous 
PA 
RBA 
pharmacological availability 
Relative bioavailability 
STZ Streptozotocin 
Tmax the time taken to reach the plasma peak level 
Cmax The plasma peak level 
MRT Mean residence time 
AUMC Area under the first moment curve 
AUC Area under the curve 
F% Relative bioavailability 
AAC Area above the curve 
ANOVA analysis of variance 
MSE Standard error of the mean 
P probability value 
Tm Melting temperature 
GIT Gastrointestinal tract 
Rd Rate of whole-body glucose disposal 
EGP endogenous glucose production 
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